DENVER – Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic n…
Source:Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC.
Thursday, January 29, 2015
Testing for EGFR mutations and ALK rearrangements is cost-effective in NSCLC.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment